Lilly Adds 10% in a Week With Q3 Eight Days Away

Eli Lilly and Company has rallied hard enough in the past week that the question entering October 29 is not whether shorts are positioned against it, but whether the pre-earnings run has already absorbed the good news.

Short sellers have made a modest and somewhat contradictory move into the stock. Shares held short rose roughly 8.5% over the past week to 7.53 million, pushing short interest from a cycle low to 0.84% of the free float. That is still a negligible level for a $1.1 trillion company. The month-long trend is actually in the opposite direction: short interest is down nearly 12% over thirty days. Borrowing cost tells a similar story of diminishing conviction, dropping 28% on the week to 0.26%. The lending pool itself is effectively open-ended, with availability far exceeding what shorts would need. There is no squeeze pressure here and no crowded-short setup worth flagging. The short score of 30.6 places LLY in the 83rd percentile on short score rank, meaning it screens as relatively low-risk from a short-side perspective.

Options positioning has moved incrementally more cautious as earnings approach. The put/call ratio reached 1.19 on Tuesday, about 1.5 standard deviations above its 20-day average of 1.17. That is a step up from the neutral reading described in last week's note, but still well short of the defensive extremes the 52-week range captures, which runs from 0.76 to 1.37. Investors are paying slightly more for downside protection than they were a fortnight ago, consistent with a stock that has gained 10% in a week against a peer median of roughly 6%.

The analyst community has been steadily raising targets in the weeks before the print. Leerink Partners lifted its target to $1,316 today while keeping its Outperform rating. Morgan Stanley raised to $1,430 and JPMorgan moved to $1,500 in late September, both maintaining Overweight. Cantor Fitzgerald went to $1,440 earlier this month. The consensus mean sits at $1,332, now only about 4% above the current price of $1,283 after the recent run. That compression in the gap to target is the central tension on the Street side: the bull case built around the incretin franchise, Mounjaro's international penetration and Zepbound script momentum is well-understood and well-priced into the consensus. The bear case, articulated with some precision by the RBC and HSBC camps, focuses on Medicare Bridge pricing dragging Zepbound net revenue below expectations and a softer Foundayo launch that required lower promotional doses to generate demand. HSBC holds a Reduce with a $940 target, a meaningful outlier against the otherwise positive consensus. The P/E multiple has expanded about 2.4 points over thirty days to 28.7x, reflecting the pre-earnings rally rather than any earnings upgrade. The 90-day EPS momentum factor ranks in the 77th percentile, while the forward year-over-year EPS growth factor ranks only in the 32nd, suggesting the near-term earnings picture is strong but the market already knows it.

Retail attention to Lilly has spiked this week. Wikipedia views and ORTEX page traffic together produce a retail attention z-score of 2.2 against Lilly's own 90-day history, a reading that reflects the volume of the stock's public conversation rather than a directional signal. Separately, Medicaid dollars reimbursed for Lilly products ran 14% above Q1 last year, based on CMS data for the period ending January 2026, a fact that frames the underlying payer-side demand before the pricing debate takes hold in the Q3 numbers.

The two most recent earnings prints give the clearest read on what Q3 day could look like. The Q2 August result produced a 6.8% one-day gain and a 9.4% five-day follow-through. The Q1 May print was more muted, up 2.7% on the day and roughly flat over five. The stock has already added 10% in the week before the Q3 release, compressing the setup relative to what followed those prior prints. Whether the reaction to Q3 is measured by what the print contains or by what was already priced in on October 20 is the data point worth watching on October 29.